174 related articles for article (PubMed ID: 26209688)
1. Aromatase inhibitors and bisphosphonates reduce deaths from breast cancer, studies show.
Kmietowicz Z
BMJ; 2015 Jul; 351():h4036. PubMed ID: 26209688
[No Abstract] [Full Text] [Related]
2. Use of aromatase inhibitors and bisphosphonates as an anticancer therapy in postmenopausal breast cancer.
Mouridsen HT; Lønning P; Beckmann MW; Blackwell K; Doughty J; Gligorov J; Llombart-Cussac A; Robidoux A; Thürlimann B; Gnant M
Expert Rev Anticancer Ther; 2010 Nov; 10(11):1825-36. PubMed ID: 20883112
[TBL] [Abstract][Full Text] [Related]
3. [Expert group consensus: prevention, diagnosis and treatment of bone loss and osteoporosis in postmenopausal breast cancer patients after aromatase inhibitor therapy].
Xiu Bing-He ;
Zhonghua Zhong Liu Za Zhi; 2013 Nov; 35(11):876-9. PubMed ID: 24447490
[No Abstract] [Full Text] [Related]
4. Potential role of bone-directed therapy on the superiority of aromatase inhibitors over tamoxifen.
Oyan B
Med Hypotheses; 2011 Dec; 77(6):1028-30. PubMed ID: 21930348
[TBL] [Abstract][Full Text] [Related]
5. Management of bone loss induced by aromatase inhibitors.
Gnant M
Cancer Invest; 2006; 24(3):328-30. PubMed ID: 16809162
[TBL] [Abstract][Full Text] [Related]
6. Aromatase inhibitors and bone health.
Bundred NJ
Curr Opin Obstet Gynecol; 2009 Feb; 21(1):60-7. PubMed ID: 19125005
[TBL] [Abstract][Full Text] [Related]
7. Loving our bones.
Sledge GW
Clin Breast Cancer; 2009 May; 9(2):71. PubMed ID: 19433385
[No Abstract] [Full Text] [Related]
8. Adjuvant bisphosphonates for early-stage breast cancer.
Brufsky A
Lancet Oncol; 2011 Jul; 12(7):610-1. PubMed ID: 21708345
[No Abstract] [Full Text] [Related]
9. Bisphosphonates and breast cancer incidence and recurrence.
Chlebowski RT; Col N
Breast Dis; 2011; 33(2):93-101. PubMed ID: 22142660
[TBL] [Abstract][Full Text] [Related]
10. Bisphosphonates in adjuvant treatment of early breast cancer.
; Harbeck N; von Minckwitz G; Thürlimann B
Crit Rev Oncol Hematol; 2010 Apr; 74 Suppl 1():S1. PubMed ID: 20427026
[No Abstract] [Full Text] [Related]
11. AZURE subgroup analysis shows adjuvant therapy with zoledronic acid may benefit breast cancer patients postmenopausal >5 years.
Oncology (Williston Park); 2011 Nov; 25(12):1212-3. PubMed ID: 22229216
[No Abstract] [Full Text] [Related]
12. Bisphosphonates in the adjuvant treatment of early breast cancer: conclusion.
Eiermann W
Crit Rev Oncol Hematol; 2010 Apr; 74 Suppl 1():S16-7. PubMed ID: 20427028
[No Abstract] [Full Text] [Related]
13. Effects of zoledronic acid on bone mineral density during aromatase inhibitor treatment of Korean postmenopausal breast cancer patients.
Lee SA; Hwang SH; Ahn SG; Lee HM; Jeong J; Lee HD
Breast Cancer Res Treat; 2011 Dec; 130(3):863-70. PubMed ID: 21861101
[TBL] [Abstract][Full Text] [Related]
14. Emerging role for bisphosphonates in cancer management.
Chlebowski RT
Breast Dis; 2011; 33(2):55-7. PubMed ID: 22142659
[No Abstract] [Full Text] [Related]
15. Breast cancer and osteoporosis.
Cheung AM; Heisey R; Srighanthan J
Curr Opin Endocrinol Diabetes Obes; 2013 Dec; 20(6):532-8. PubMed ID: 24468755
[TBL] [Abstract][Full Text] [Related]
16. Bone modifying agents in postmenopausal breast cancer patients treated with aromatase inhibitors: beyond bone protection?
Villasco A; Minella C; Bounous VE; Rosso R; Biglia N
Breast Dis; 2023; 42(1):1-4. PubMed ID: 36806500
[TBL] [Abstract][Full Text] [Related]
17. The role of bisphosphonates in the adjuvant setting for breast cancer.
Reeder JG; Brufsky AM
Oncology (Williston Park); 2010 May; 24(6):462-7, 475. PubMed ID: 20568587
[TBL] [Abstract][Full Text] [Related]
18. Routine adjuvant use of bisphosphonates in breast cancer arguments in favour and against.
Diel I; Aebi S
Crit Rev Oncol Hematol; 2010 Apr; 74 Suppl 1():S11-5. PubMed ID: 20427027
[No Abstract] [Full Text] [Related]
19. Adjuvant therapy with bone-targeted agents.
Wilson C; Coleman RE
Curr Opin Support Palliat Care; 2011 Sep; 5(3):241-50. PubMed ID: 21785355
[TBL] [Abstract][Full Text] [Related]
20. [Antitumour effects of bisphosphonates in breast cancer].
van de Ven S; Kroep JR; Hamdy NA; Sleeboom HP; Nortier HW
Ned Tijdschr Geneeskd; 2010; 154():A1951. PubMed ID: 21083955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
